“It is also suggested that … labile forms of Fe or Cu ions, such as non transferrin-bound iron (NTBI) or intracellular low molecular weight labile … among the main factors that may cause variations in the therapeutic response to HU in cancer, sickle cell anemia, … and other groups of patients.”